Phase1/2 study of an anti-galectin-9 antibody, LYT-200, in patients with metastatic solid tumors

Category Primary study
JournalJournal for ImmunoTherapy of Cancer
Year 2021
This article has no abstract
Epistemonikos ID: 20ba5f87251c08489ffbfc2bc0a77c21b335ccfc
First added on: Feb 13, 2025